ArticlePloS one2026
Identifying gene regulation modules associated with tumor metastasis using a network decomposition approach and combinatorial fusion analysis.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We systematically evaluated whether modular decomposition of molecular networks into gene regulatory modules (GRMs) enables the identification of metastasis‑associated genes. We developed an efficient bioinformatics framework that integrates subgraph extraction with combinatorial fusion analysis (CFA) to identify and prioritize metastasis‑associated GRMs in cancer networks. We validated top‑ranked GRMs using cancer hallmark annotations, enrichment analysis, drug-target associations, and survival data, and assessed GRM cooperativity through comparisons with prior metastasis studies. The proposed approach consistently outperformed existing methods in identifying metastasis‑associated GRMs. Robustness analyses across ten feature combinations and comparisons between three‑node and four‑node GRMs confirmed stable performance under diverse settings. Application to three independent KIRC metastasis cohorts further demonstrated improved identification of metastasis‑related GRMs. Overall, this integrated GRM‑based framework reliably captures coordinated regulatory patterns linked to metastasis and shows potential for identifying clinically relevant target genes and therapeutic drug candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.